Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11964125 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2KDM4EPOLBMAPT | |
| SCHEMBL20083753 | 0.75 | TSHR (0.49) | ALDH1A1SMN1; SMN2KDM4EPOLBMAPT | |
| SCHEMBL9965999 | 0.74 | — | — | |
| SCHEMBL20083782 | 0.74 | — | — | |
| SCHEMBL20083825 | 0.73 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2KDM4EPOLBMAPT | |
| SCHEMBL22091424 | 0.73 | MEN1 (0.51) | ALDH1A1SMN1; SMN2KDM4EPOLBMAPT | |
| SCHEMBL27453621 | 0.72 | KDM4C (0.55) | ALDH1A1SMN1; SMN2KDM4EPOLBMAPT | |
| SCHEMBL10436837 | 0.71 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPTADORA2BUSP7 | |
| SCHEMBL28059053 | 0.69 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KDM4EMAPTTBXAS1 | |
| SCHEMBL1155646 | 0.69 | ALDH1A1 (0.46) | ALDH1A1KDM4EPOLBMAPTCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20210277030-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-06 | — | — | US | disclosed |
| US-10472376-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170107240-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-5736535-A | 1-pyrimidinylacetamide compounds which are inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 1998-04-07 | — | — | US | disclosed |
| EP-0636143-B1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LTD (GB) | 1997-09-24 | — | — | EP | disclosed |
| EP-0636141-B1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS | ZENECA LTD (GB) | 1997-06-25 | — | — | EP | disclosed |
| US-5441960-A | 1-pyrimidinylacetamide human leukocyte elastate inhibitors | ZENECA LIMITED (GB) | 1995-08-15 | — | — | US | disclosed |
| EP-0636143-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS. | ZENECA LTD (GB) | 1995-02-01 | — | — | EP | disclosed |
| EP-0636141-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS. | ZENECA LTD (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021214-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021210-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| US-5254558-A | Substituted 1,3-diazines as leukocyte elastase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0528633-A1 | Pyrimidinyl acetamides as elastase inhibitors | ZENECA LIMITED (GB) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | ALDH1A1 210/4885SMN1; SMN2 4127/4885KDM4E 925/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | ALDH1A1 210/4885SMN1; SMN2 4127/4885KDM4E 925/4885 |
| US-20170107240-A1 | AMIDE COMPOUND | RORB, RORC, RORA | ALDH1A1 380/4885SMN1; SMN2 4136/4885KDM4E 740/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | ALDH1A1 210/4885SMN1; SMN2 4127/4885KDM4E 925/4885 |
| US-20210277030-A1 | AMIDE COMPOUND | RORB, RORC, RORA | ALDH1A1 380/4885SMN1; SMN2 4136/4885KDM4E 740/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | ALDH1A1 232/4885SMN1; SMN2 3917/4885KDM4E 1419/4885 |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | RORC, RORB, RORA | ALDH1A1 336/4885SMN1; SMN2 4241/4885KDM4E 1432/4885 |
| US-10472376-B2 | Amide compound | RORB, RORC, RORA | ALDH1A1 380/4885SMN1; SMN2 4136/4885KDM4E 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.